Serum levels of tumour necrosis factor-α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome

Clinical and Laboratory Haematology

Volumn 19, Issue 3, 1997, Pages 197-201

  Stasi, R ^a,b   Brunetti, M ^a   Bussa, S ^a   Conforti, M ^a   Martin, L S ^a   La Presa, M ^a   Bianchi, M ^a   Parma, A ^a   Pagano, A ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Erythropoietin; Interleukin 1 ; Myelodysplastic syndrome; Treatment; Tumour necrosis factor

Indexed keywords

FERRITIN; INTERLEUKIN 1BETA; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INTERLEUKIN-1; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030923572     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2257.1997.tb00007.x     Document Type: Article

References (25)

1. Aul C., Arning M., Runde V. & Schneider W. (1991) Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leukemia Research 15, 571-575.
2. Bennett J.M., Catovsky D., Daniel M.T. et al. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology 51, 189-199.
3. Bessho M., Jinnai I., Matsuda A., Saito M. & Hiroshima K. (1990) Improvement of anemia by recombinant human erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. International Journal of Cell Cloning 8, 445-458.
4. Depaoli L., Levis A., Isabella N. et al (1993) Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes. Haematologica 78, 118-122.
5. Eridani S. & Montagna C. (1995) Erythropoietic regulation: an overview. In Disorders of the Erythropoiesis: Therapeutical Implications. Grossi et al., eds. Milan: Wichtig Editore: 1993, 1-4.
6. Erslev A.J. (1991) Erythropoietin. New England Journal of Medicine 324, 1339-1344.
7. Faquin W.C., Scheider T.J. & Goldberg M.A. (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79, 1987-1994.
8. Ghio R., Balleari H., Ballestrero A. et al. (1993) Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematologica 90, 58-64.
9. Hellstrom-Lindberg E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology 89, 67-71.
10. Isnard F., Najman A., Jaar B. et al. (1994) Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leukemia and Lymphoma 12, 307-314.
11. Jacobs A., Janowska-Wieczorek A., Caro J., Bowen D.J. & Lewis T. (1989) Circulating erythropoietin in patients with myelodysplastic syndromes. British Journal of Haematology 73, 36-39.
12. Kurzrock R., Talpaz M., Estey E. et al. (1991) Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 5, 985-990.
13. Legare R.D. & Gilliland D.G. (1995) Myelodysplastic syndrome. Current Opinion in Hematology 2, 283-292.
14. Means R.T. & Krantz S.B. (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80, 1639-1647.
15. Miller C.B., Jones I.Q., Piantadosi S., Abeloff M.D. & Spivak J.L. (1990) Decreased erythropoietin response in patients with the anemia of cancer. New England Journal of Medicine 322, 1689-1692.
16. Miller A.B., Hoogstraten B., Staquet M. & Winkler A. (1981) Reporting results of cancer treatment. Cancer 47, 207-214.
17. Rose E.H., Abels R.I., Nelson R.A., McCullough D.M. & Lessin L. (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). British Journal of Haematology 89, 831-837.
18. Stasi R., Zinzani P.L., Galieni P. et al. S. (1995) Clinical implications of cytokine and soluble receptor or measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. European Journal of Haematology 54, 9-17.
19. Stein R.S., Abels R.I. & Krantz S.B. (1991) Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78, 1658-1663.
20. Stenke L., Wallvik J., Celsing F. & Hast R. (1993) Prediction of response to treatment with recombinant human erythropoietin in myelodysplastic syndromes. Leukemia 7, 1324-1327.
21. Stone R.M., Bernstein S.H. et al. (1994) Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukema Research 18, 769-776.
22. Van Kamp H., Prinsze-Postema T.C., Kluin P.M. et al. (1991) Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. British Journal of Haematology 78, 488-493.
23. Verhoef G.E.G., De Schouwer P., Ceuppens J.L., Van Damme A., Grossens W. & Boogaerts M. A. (1992b) Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6, 1268-1272.
24. Verhoef G.E.G., Zachee P., Ferrant A. et al. (1992a) Recombinant human erythropoietin in patients with myelodysplastic syndrome: a clinical and erythrokinetic assessment. Annals of Hematology 64, 16-21.
25. Zoumbos N., Symeonidis A. & Kourakli A. (1991) Increased levels of serum interleukin-2 receptor and tumor necrosis factor in serum of patients with myelodysplastic syndromes. Blood 77, 413-414.